Physician profile
Gregory Cain Bratton
NPI 1861657355
$26,050.07
in general payments reported to CMS, 2019-2025
79 companies · $2,231 in 2025
The $2,231 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,592 · 2020: $5,739 · 2021: $8,491 · 2022: $2,123 · 2023: $2,208 · 2024: $3,665 · 2025: $2,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,585 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,585.23 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,452.71 | 2019-2021 | |
| Abbvie INC. | $6,452.87 | 2019-2025 | Linzess, Vraylar, Viberzi |
| Henry Schein, INC. | $1,500.00 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $1,440.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $952.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $717.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $714.42 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.94 | 2019-2025 | Jardiance |
| Corium, LLC | $413.99 | 2022-2025 | Azstarys |
| Pfizer INC. | $332.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $252.88 | 2019-2025 | Trelegy Ellipta |
| Almatica Pharma LLC | $249.23 | 2021-2024 | Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $240.22 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $215.86 | 2020-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $213.42 | 2022-2024 | Qelbree, Qelbree, Xyosted |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Bratton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.